Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-08-17

Edwards Lifesciences Corp (EW)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$17,454,255
Bernard Zovighian total, FY2025
53rd
CEO pay percentile vs peers
194:1
CEO-to-median pay ratio
89.3%
Say-on-pay support, latest vote
Companies that benchmark against EW
25 companies name EW as a compensation peer

Each company listed discloses EW in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named EW in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Bernard Zovighian$1,192,500$0$7,167,024$6,499,109$2,406,537$0$189,085$17,454,255
Chief Executive Officer and Director
Scott Ullem807,89802,205,2381,999,726966,435071,2576,050,554
Corporate Vice President, Chief Financial Officer
Larry Wood635,91901,818,4991,648,710689,382061,8294,854,339
Former Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart
Daveen Chopra671,04201,764,0661,375,784824,239060,6114,695,742
Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies
Donald Bobo759,78301,378,2741,249,829786,899048,5804,223,365
Corporate Vice President, Strategy & Corporate Development
Annette Brüls726,58601,020,334924,995719,581158,905181,7063,732,107
Corporate Vice President, EMEACLA

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Bernard Zovighian$17,454,255$14,579,474$12,869,020+2,874,781
Scott Ullem6,050,5545,303,1835,949,153+747,371
Larry Wood4,854,3394,608,6615,395,034+245,678
Daveen Chopra4,695,7423,720,491+975,251
Donald Bobo4,223,365
Annette Brüls3,732,107

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Donald BoboCVP,Strategy/Corp Development2026-04-02D22,680$0$0Derivative, Class A CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-04-02A22,680591,343,942CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-04-02D4,67681376,846Common, open-market saleForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-04-02D18,004801,441,209Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-04-06D1,0198182,523Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-04-06A1,0195960,383CommonForm 4 ↗
Dividend-equivalent accruals2026-04-061,0191 insider, 1 accrual row
Scott UllemCVP, Chief Financial Officer2026-04-09D4,67680376,401Common, open-market saleForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-04-09D13,00000Derivative, Class A CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-04-09A13,00059770,337CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-04-09D8,32480664,144Common, open-market saleForm 4 ↗
Dividend-equivalent accruals2026-05-012,0381 insider, 2 accrual rows
Daniel J. LippisCVP, TAVR2026-05-01A1,0195960,383CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01D19841,596Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01D1,0198485,576CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01D2528421,163CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01D1,0008382,989Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01A1,0195960,383CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-03D4698439,387CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-03D2828423,682CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-03A13,00059770,337CommonForm 4 ↗
Bernard ZovighianDirector2026-05-03D52300CommonForm 4 ↗
Bernard ZovighianDirector2026-05-03A52300CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-03D11,13183922,871CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-03D13,00000Derivative, Class A CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-03D6208452,068CommonForm 4 ↗
Bernard ZovighianDirector2026-05-03D5158443,250CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-07D6748356,077CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07D5,39883446,738CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-05-07A5,20000Derivative, Class A CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-07A39,90000Derivative, Class A CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-07D1,1418394,429CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07A4,22200CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-07A7,85000Derivative, Class A CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-07D1,37383114,234CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-07D1,0388385,905CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-07A44,00000Derivative, Class A CommonForm 4 ↗
Annette BrulsCVP, EMEACLA2026-05-07A6,65000Derivative, Class A CommonForm 4 ↗
Annette BrulsCVP, EMEACLA2026-05-07A33,70000Derivative, Class A CommonForm 4 ↗
Annette BrulsCVP, EMEACLA2026-05-07D84836,952CommonForm 4 ↗
Annette BrulsCVP, EMEACLA2026-05-07A6,65000CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-07A9,67500Derivative, Class A CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-07A49,10000Derivative, Class A CommonForm 4 ↗
Andrew M. DahlSVP, Corporate Controller2026-05-07D2898323,918CommonForm 4 ↗
Andrew M. DahlSVP, Corporate Controller2026-05-07A3,02000CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-07A7,85000Derivative, Class A CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-05-07D2648321,965CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-05-07D5938047,280CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07A43,80000CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07D4,15383345,530CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07D5,48900CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07A43,80000Derivative, Class A CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-07A7,85000CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-07D1,66183137,464CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-07A9,67500CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-07D3098325,709CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-05-07D2268318,704CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07A5,48900CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-05-07A26,40000Derivative, Class A CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-05-07A5,20000CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-07A7,85000CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-07D4508337,242CommonForm 4 ↗
Andrew M. DahlSVP, Corporate Controller2026-05-07A3,98500CommonForm 4 ↗
Andrew M. DahlSVP, Corporate Controller2026-05-07A6,74500Derivative, Class A CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-07D8318369,139CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07D4,22200CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07A245,30000Derivative, Class A CommonForm 4 ↗
Nicholas J. ValerianiDirector2026-05-08A5,12700CommonForm 4 ↗
Kieran T. GallahueDirector2026-05-08A3,25100CommonForm 4 ↗
Kieran T. GallahueDirector2026-05-08A1,06400CommonForm 4 ↗
Heisz Leslie StoneDirector2026-05-08A3,25100CommonForm 4 ↗
Ramona SequeiraDirector2026-05-08A3,25100CommonForm 4 ↗
Steven R. LorangerDirector2026-05-08A1,06400CommonForm 4 ↗
Paul A. LaVioletteDirector2026-05-08A3,25100CommonForm 4 ↗
David T. FeinbergDirector2026-05-08A3,25100CommonForm 4 ↗
Leslie C. DavisDirector2026-05-08A3,25100CommonForm 4 ↗
Steven R. LorangerDirector2026-05-08A3,25100CommonForm 4 ↗
Bernard ZovighianDirector2026-05-11A47,20700CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-11D19,83000Derivative, Class A CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-11D3628028,946CommonForm 4 ↗
Bernard ZovighianDirector2026-05-11A26,64000CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-11D11,00480879,880CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-11D7,53880602,738CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-11D7,46980597,221CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-11A13,45700CommonForm 4 ↗
Bernard ZovighianDirector2026-05-11D26,64000CommonForm 4 ↗
Bernard ZovighianDirector2026-05-11D26,198802,094,792CommonForm 4 ↗
Bernard ZovighianDirector2026-05-11D35,506782,766,762Common, open-market saleForm 4 ↗
Bernard ZovighianDirector2026-05-11D47,20700Derivative, Class A CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-11A13,58300CommonForm 4 ↗
Bernard ZovighianDirector2026-05-11D8457866,250Common, open-market saleForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-11D13,45700Derivative, Class A CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-11D13,58300Derivative, Class A CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-11A19,83000CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-15D8,00082654,573CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-15D9,96882818,106Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-18D6208150,307CommonForm 4 ↗
Dividend-equivalent accruals2026-05-186201 insider, 1 accrual row
Daniel J. LippisCVP, TAVR2026-05-18A6207345,062CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-22D1,50085126,905Common, open-market saleForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-27D23,145862,000,193Common, open-market saleForm 4 ↗
Andrew M. DahlSVP, Corporate Controller2026-05-29D567.538648,853CommonForm 4 ↗
Bernard ZovighianDirector2026-06-17D5238845,982CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-06-30A6197344,989CommonForm 4 ↗
Dividend-equivalent accruals2026-06-306191 insider, 1 accrual row
Daniel J. LippisCVP, TAVR2026-06-30D6199156,577Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-07-07D3779535,883CommonForm 4 ↗
Theodora MistrasCVP, Chief Financial Officer2026-07-09A12,32500CommonForm 4 ↗
Theodora MistrasCVP, Chief Financial Officer2026-07-09A87,59500CommonForm 4 ↗
Theodora MistrasCVP, Chief Financial Officer2026-07-09A61,80000Derivative, Class A CommonForm 4 ↗
Theodora MistrasCVP, Chief Financial Officer2026-07-09A12,32500Derivative, Class A CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-07-10A6197344,989CommonForm 4 ↗
Dividend-equivalent accruals2026-07-106191 insider, 1 accrual row
Daniel J. LippisCVP, TAVR2026-07-10D6199256,762CommonForm 4 ↗
Annette BrulsCVP, EMEACLA2026-07-11D1099210,051CommonForm 4 ↗
Bernard ZovighianDirector2026-07-27D2,920.5584245,134CommonForm 4 ↗
Bernard ZovighianDirector2026-07-27D319.6500CommonForm 4 ↗
Bernard ZovighianDirector2026-07-27A319.6500CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-07-28A9,62874712,665CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-07-28D9,62885818,958CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-07-28D9,62800Derivative, Class A CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-07-30D146.318612,588CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 123 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Donald BoboCVP,Strategy/Corp Development2026-04-02D22,680$0$0Derivative, Class A CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-04-02A22,680591,343,942CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-04-02D4,67681376,846Common, open-market saleForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-04-02D18,004801,441,209Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-04-06D1,0198182,523Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-04-06A1,0195960,383CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-04-06D1,01900Derivative, Class A CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-04-09D4,67680376,401Common, open-market saleForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-04-09D13,00000Derivative, Class A CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-04-09A13,00059770,337CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-04-09D8,32480664,144Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01D1,01900Derivative, Class A CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01A1,0195960,383CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01D19841,596Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01D1,0198485,576CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01D2528421,163CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01D1,01900Derivative, Class A CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01D1,0008382,989Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-01A1,0195960,383CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-03D4698439,387CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-03D2828423,682CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-03A13,00059770,337CommonForm 4 ↗
Bernard ZovighianDirector2026-05-03D52300CommonForm 4 ↗
Bernard ZovighianDirector2026-05-03A52300CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-03D11,13183922,871CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-03D13,00000Derivative, Class A CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-03D6208452,068CommonForm 4 ↗
Bernard ZovighianDirector2026-05-03D5158443,250CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-07D6748356,077CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07D5,39883446,738CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-05-07A5,20000Derivative, Class A CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-07A39,90000Derivative, Class A CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-07D1,1418394,429CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07A4,22200CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-07A7,85000Derivative, Class A CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-07D1,37383114,234CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-07D1,0388385,905CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-07A44,00000Derivative, Class A CommonForm 4 ↗
Annette BrulsCVP, EMEACLA2026-05-07A6,65000Derivative, Class A CommonForm 4 ↗
Annette BrulsCVP, EMEACLA2026-05-07A33,70000Derivative, Class A CommonForm 4 ↗
Annette BrulsCVP, EMEACLA2026-05-07D84836,952CommonForm 4 ↗
Annette BrulsCVP, EMEACLA2026-05-07A6,65000CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-07A9,67500Derivative, Class A CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-07A49,10000Derivative, Class A CommonForm 4 ↗
Andrew M. DahlSVP, Corporate Controller2026-05-07D2898323,918CommonForm 4 ↗
Andrew M. DahlSVP, Corporate Controller2026-05-07A3,02000CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-07A7,85000Derivative, Class A CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-05-07D2648321,965CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-05-07D5938047,280CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07A43,80000CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07D4,15383345,530CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07D5,48900CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07A43,80000Derivative, Class A CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-07A7,85000CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-07D1,66183137,464CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-07A9,67500CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-07D3098325,709CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-05-07D2268318,704CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07A5,48900CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-05-07A26,40000Derivative, Class A CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-05-07A5,20000CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-07A7,85000CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-07D4508337,242CommonForm 4 ↗
Andrew M. DahlSVP, Corporate Controller2026-05-07A3,98500CommonForm 4 ↗
Andrew M. DahlSVP, Corporate Controller2026-05-07A6,74500Derivative, Class A CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-07D8318369,139CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07D4,22200CommonForm 4 ↗
Bernard ZovighianDirector2026-05-07A245,30000Derivative, Class A CommonForm 4 ↗
Nicholas J. ValerianiDirector2026-05-08A5,12700CommonForm 4 ↗
Kieran T. GallahueDirector2026-05-08A3,25100CommonForm 4 ↗
Kieran T. GallahueDirector2026-05-08A1,06400CommonForm 4 ↗
Heisz Leslie StoneDirector2026-05-08A3,25100CommonForm 4 ↗
Ramona SequeiraDirector2026-05-08A3,25100CommonForm 4 ↗
Steven R. LorangerDirector2026-05-08A1,06400CommonForm 4 ↗
Paul A. LaVioletteDirector2026-05-08A3,25100CommonForm 4 ↗
David T. FeinbergDirector2026-05-08A3,25100CommonForm 4 ↗
Leslie C. DavisDirector2026-05-08A3,25100CommonForm 4 ↗
Steven R. LorangerDirector2026-05-08A3,25100CommonForm 4 ↗
Bernard ZovighianDirector2026-05-11A47,20700CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-11D19,83000Derivative, Class A CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-11D3628028,946CommonForm 4 ↗
Bernard ZovighianDirector2026-05-11A26,64000CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-11D11,00480879,880CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-11D7,53880602,738CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-11D7,46980597,221CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-11A13,45700CommonForm 4 ↗
Bernard ZovighianDirector2026-05-11D26,64000CommonForm 4 ↗
Bernard ZovighianDirector2026-05-11D26,198802,094,792CommonForm 4 ↗
Bernard ZovighianDirector2026-05-11D35,506782,766,762Common, open-market saleForm 4 ↗
Bernard ZovighianDirector2026-05-11D47,20700Derivative, Class A CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-11A13,58300CommonForm 4 ↗
Bernard ZovighianDirector2026-05-11D8457866,250Common, open-market saleForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-11D13,45700Derivative, Class A CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-11D13,58300Derivative, Class A CommonForm 4 ↗
Scott UllemCVP, Chief Financial Officer2026-05-11A19,83000CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-15D8,00082654,573CommonForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-15D9,96882818,106Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-18D6208150,307CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-18D62000Derivative, Class A CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-05-18A6207345,062CommonForm 4 ↗
Daveen ChopraCVP, TMTT & Surgical2026-05-22D1,50085126,905Common, open-market saleForm 4 ↗
Donald BoboCVP,Strategy/Corp Development2026-05-27D23,145862,000,193Common, open-market saleForm 4 ↗
Andrew M. DahlSVP, Corporate Controller2026-05-29D567.538648,853CommonForm 4 ↗
Bernard ZovighianDirector2026-06-17D5238845,982CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-06-30A6197344,989CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-06-30D61900Derivative, Class A CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-06-30D6199156,577Common, open-market saleForm 4 ↗
Daniel J. LippisCVP, TAVR2026-07-07D3779535,883CommonForm 4 ↗
Theodora MistrasCVP, Chief Financial Officer2026-07-09A12,32500CommonForm 4 ↗
Theodora MistrasCVP, Chief Financial Officer2026-07-09A87,59500CommonForm 4 ↗
Theodora MistrasCVP, Chief Financial Officer2026-07-09A61,80000Derivative, Class A CommonForm 4 ↗
Theodora MistrasCVP, Chief Financial Officer2026-07-09A12,32500Derivative, Class A CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-07-10A6197344,989CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-07-10D61900Derivative, Class A CommonForm 4 ↗
Daniel J. LippisCVP, TAVR2026-07-10D6199256,762CommonForm 4 ↗
Annette BrulsCVP, EMEACLA2026-07-11D1099210,051CommonForm 4 ↗
Bernard ZovighianDirector2026-07-27D2,920.5584245,134CommonForm 4 ↗
Bernard ZovighianDirector2026-07-27D319.6500CommonForm 4 ↗
Bernard ZovighianDirector2026-07-27A319.6500CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-07-28A9,62874712,665CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-07-28D9,62885818,958CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-07-28D9,62800Derivative, Class A CommonForm 4 ↗
Wayne MarkowitzCVP, JAPAC2026-07-30D146.318612,588CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Bernard ZovighianPSU2025-05-083,250,137$3,250,137
Scott UllemOPTION2025-05-086375,2001,999,726
Daveen ChopraOPTION2025-05-086347,0001,375,784
Larry WoodPSU2025-05-08824,662824,662
Larry WoodOPTION2025-05-086362,0001,648,710
Daveen ChopraPSU2025-05-08827,448827,448
Larry WoodPSU2025-05-08993,837993,837
Bernard ZovighianPSU2025-05-083,916,8873,916,887
Bernard ZovighianOPTION2025-05-0863244,4006,499,109
Scott UllemPSU2025-05-081,000,0421,000,042
Scott UllemPSU2025-05-081,205,1961,205,196
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Bernard Zovighian$0$7,167,024$6,499,10952.4%
Scott Ullem02,205,2381,999,72652.4%
Daveen Chopra0827,4481,375,78437.6%
Larry Wood01,818,4991,648,71052.4%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Scott UllemRSU1,250$106,563
Donald BoboRSU94480,476
Donald BoboRSU35,4003,017,850
Scott UllemRSU97182,778
Daveen ChopraRSU3,238276,040
Annette BrülsOption31,60074.63
Bernard ZovighianOption196,88074.63
Daveen ChopraOption27,90085.84
Bernard ZovighianOption133,80085.84
Scott UllemOption36,45088.78
Bernard ZovighianPSU80,9766,903,204
Bernard ZovighianRSU76,2136,497,116
Bernard ZovighianRSU158,97613,552,619
Bernard ZovighianRSU49,2634,199,628
Scott UllemRSU55,2194,707,399
Scott UllemPSU28,6532,442,668
Daveen ChopraPSU21,7061,850,437
Daveen ChopraRSU37,2753,177,694
Larry WoodRSU19,3381,648,522
Donald BoboRSU14,6561,249,445
Donald BoboPSU17,5571,496,734
Daveen ChopraRSU16,1001,372,525
Donald BoboRSU14,0441,197,230
Annette BrülsPSU12,2601,045,165
Bernard ZovighianRSU11,263960,171
Annette BrülsRSU10,850924,963
Donald BoboRSU8,375713,969
Annette BrülsRSU6,200528,550
Daveen ChopraRSU7,000596,750
Donald BoboRSU6,700571,175
Scott UllemOption60,57974.63
Daveen ChopraOption47,00074.63
Donald BoboRSU5,025428,381
Donald BoboOption37,86274.63
Donald BoboRSU3,213273,908
Daveen ChopraRSU3,205273,226
Bernard ZovighianRSU1,03888,490
Daveen ChopraRSU81369,308
Bernard ZovighianOption8,425105.93
Scott UllemOption10,150105.93
Donald BoboOption7,53088.78
Scott UllemOption30,93285.84
Annette BrülsOption16,43392.85
Donald BoboOption18,70185.84
Daveen ChopraOption24,95088.78
Daveen ChopraOption6,600105.93
Bernard ZovighianRSU43,5503,712,638
Bernard ZovighianRSU33,5002,855,875
Bernard ZovighianRSU25,1252,141,906
Scott UllemRSU23,4501,999,113
Scott UllemRSU20,6941,764,142
Larry WoodRSU17,0191,450,848
Daveen ChopraRSU14,1751,208,419
Scott UllemRSU13,4001,142,350
Scott UllemRSU11,075944,144
Daveen ChopraRSU9,200784,300
Larry WoodRSU8,725743,806
Scott UllemRSU8,307708,172
Annette BrülsRSU6,060516,615
Annette BrülsRSU5,477466,914
Daveen ChopraRSU5,250447,563
Scott UllemRSU4,725402,806
Bernard ZovighianOption86,85088.78
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation programs are designed to emphasize performance-based compensation, reward financial performance and the implementation of our corporate strategy, and to align the financial interests of our executives with those of our long-term stockholders.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultantSemler Brossy Consulting Group
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-07424,961,63950,924,101089.3%Passed
20252025-05-08412,893,48056,265,224088.01%Passed
20242024-05-07433,346,23542,323,309091.1%Passed
20232023-05-11438,121,67043,074,168091.05%Passed
20222022-05-03450,501,74449,851,5151,494,85289.77%Passed
20212021-05-04465,845,85335,298,5241,387,56492.7%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-0789.3%a
20252025-05-0888.01%b
20242024-05-0791.1%c

a. Approved under the standard stated in the filing — “Advisory Vote to Approve Named Executive Officer Compensation • Majority of shares represented at the Annual Meeting and entitled to vote on the proposal • Abstentions will have the effect of votes "against" • Broker non-votes will not be counted as shares entitled to vote on the proposal and therefore will have no effect on the outcome of the proposal Proposal 3.”.

b. Approved under the standard stated in the filing — “Advisory Vote to Approve Named Executive Officer Compensation • Majority of shares represented at the Annual Meeting and entitled to vote on the proposal • Abstentions will have the effect of votes "against" • Broker non-votes will not be counted as shares entitled to vote on the proposal Proposal 3.”.

c. Approved under the standard stated in the filing — “Advisory Vote to Approve Named Executive Officer Compensation • Majority of shares represented at the Annual Meeting and entitled to vote on the proposal • Abstentions will have the effect of votes "against" • Broker non-votes will not be counted as shares entitled to vote on the proposal Proposal 3.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)194 : 1
CEO total compensation$17,454,255
Median employee compensation$89,827
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Nicholas J. ValerianiIndependent · Board Chair · Compensation and Governance$85,000$409,956$0$0$0$494,956
Leslie S. HeiszIndependent · Audit (Chair)115,000259,943000374,943
Paul A. LaVioletteIndependent · Compensation and Governance (Chair)105,000259,943000364,943
Kieran T. GallahueIndependent · Audit90,027259,943000349,970
David T. FeinbergIndependent · Audit90,000259,943000349,943
Ramona SequeiraIndependent · Audit90,000259,943000349,943
Steven R. LorangerIndependent · Compensation and Governance85,027259,943000344,970
Leslie C. DavisIndependent · Compensation and Governance85,000259,943000344,943
Bernard ZovighianEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer
Annual equity retainer
Per board meeting fee$1,500
Committee chair fees (audit / comp / nom-gov)25,000 / 20,000 / 20,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$745,054
Equity awards (grant-date value)$2,229,557
All other compensation$0
Total cost of the board$2,974,611

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Edwards Lifesciences Corp names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Edwards Lifesciences Corp.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Baxter International Inc.2025Andrew Hider$499,315$23,133,518$3,185,053$820,125$29,805,182
2Abbott Laboratories2025Robert Ford1,500,0008,787,3788,788,4301,968,75024,198,660
3Boston Scientific Corporation2025Michael Mahoney1,442,60313,608,0563,749,9804,002,00123,532,050
4Medtronic plc2026Geoffrey Martha1,399,03913,672,2005,175,5592,307,20022,940,252
5Stryker Corporation2025Kevin Lobo1,500,00016,684,91702,250,00021,401,495
6Intuitive Surgical, Inc.2025David Rosa858,75018,674,87201,373,85920,997,480
7Align Technology, Inc.2025Joseph Hogan1,400,00016,556,87201,220,10019,193,988
8GE Healthcare Technologies Inc.2025Peter Arduini1,324,98311,249,5333,624,9702,081,08418,562,794
9Edwards Lifesciences Corp2025Bernard Zovighian1,192,5007,167,0246,499,1092,406,53717,454,255
10Becton, Dickinson and Company2025Thomas Polen1,395,4639,991,8543,311,8611,852,01017,129,140
11Zimmer Biomet Holdings, Inc.2025Ivan Tornos1,281,84612,000,10102,420,76716,106,550
12The Cooper Companies, Inc.2025Albert White III1,170,7696,642,9186,643,0501,525,95116,051,141
13Hologic, Inc.2024Stephen MacMillan1,212,6289,141,4682,937,4771,990,41315,819,261
14ResMed Inc.2025Michael Farrell1,214,1508,775,0592,925,0071,646,74314,674,543
15IDEXX Laboratories, Inc.2025Jonathan Mazelsky1,150,0005,399,8815,400,0012,593,00014,580,122
16Agilent Technologies, Inc.2025Padraig McDonnell1,141,3458,169,8502,017,7591,436,80912,827,236
17Illumina, Inc.2025Jacob Thaysen1,000,0008,763,12201,155,00011,018,895
18DexCom, Inc.2025Jacob Leach768,9625,936,06201,164,7807,985,960

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Edwards Lifesciences Corp127%Options 50 · PSU 25 · RSU 25NoSemler Brossy Consulting Group
Abbott Laboratories75.0%Options 50 · PSU 50NoMeridian Compensation Partners, LLC
Agilent Technologies, Inc.not disclosedPSU 60 · Options 20 · RSU 20NoSemler Brossy
Align Technology, Inc.58.1%MSU 70 · RSU 30Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite IndexCompensia, Inc.
Baxter International Inc.not disclosedPSU 50 · Stock Options 25 · RSU 25not disclosedAon
Becton, Dickinson and Company85%PSU 50 · Options 25 · RSU 25NoSemler Brossy
Boston Scientific Corporation173%PSU 50 · RSU 25 · Options 25NoSemler Brossy Consulting Group, LLC
DexCom, Inc.not disclosednot disclosedYes — Relative TSR Performance MetricAon Hewitt Consulting Company
GE Healthcare Technologies Inc.101%PSU 50 · Options 25 · RSU 25NoSemler Brossy
Hologic, Inc.109%PSU 50 · RSU 25 · Options 25Nonot disclosed
IDEXX Laboratories, Inc.140%Options 50 · PSU 50NoFarient
Illumina, Inc.1155%not disclosedYes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology IndexAon (Aon's Human Capital Practice, a division of Aon, plc)
Intuitive Surgical, Inc.115.2%RSU 50 · PSU 50NoAon
Medtronic plc103%PSU 50 · Options 30 · RSU 20NoSemler Brossy
ResMed Inc.102%PSU 50 · RSU 25 · Options 25Yes — Absolute TSRFW Cook, Inc.
Stryker Corporation100%PSU 48 · Options 34NoSemler Brossy
The Cooper Companies, Inc.100.9%Options 50 · PSU 50NoCompensia
Zimmer Biomet Holdings, Inc.125.9%RSU 50 · PSU 50Yes — Relative TSRSemler Brossy

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Bernard ZovighianDEF 14A2026-03-260001099800-26-000015Section “Summary Compensation Table – Fiscal 2023-2025”. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451
2Section 01, Scott UllemDEF 14A2026-03-260001099800-26-000015Section “Summary Compensation Table – Fiscal 2023-2025”. As printed: 6,050,554. Filing ↗machine: r5 · c27 · span 972045–972054
3Section 01, Larry WoodDEF 14A2026-03-260001099800-26-000015Section “Summary Compensation Table – Fiscal 2023-2025”. As printed: 4,854,339. Filing ↗machine: r15 · c27 · span 992711–992720
4Section 01, Daveen ChopraDEF 14A2026-03-260001099800-26-000015Section “Summary Compensation Table – Fiscal 2023-2025”. As printed: 4,695,742. Filing ↗machine: r13 · c27 · span 988051–988060
5Section 01, Donald BoboDEF 14A2026-03-260001099800-26-000015Section “Summary Compensation Table – Fiscal 2023-2025”. As printed: 4,223,365. Filing ↗machine: r8 · c27 · span 978450–978459
6Section 01, Annette BrülsDEF 14A2026-03-260001099800-26-000015Section “Summary Compensation Table – Fiscal 2023-2025”. As printed: 3,732,107. Filing ↗machine: r11 · c27 · span 985105–985114
7Section 03, Bernard Zovighian PSUDEF 14A2026-03-260001099800-26-000015Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r4 · c2 · span 911028–911037
8Section 03, Scott Ullem OPTIONDEF 14A2026-03-260001099800-26-000015Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t62 · r5 · c5 · span 971224–971233
9Section 03, Daveen Chopra OPTIONDEF 14A2026-03-260001099800-26-000015Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t96 · r1 · c1 · span 1837081–1837087
10Section 03, Larry Wood PSUDEF 14A2026-03-260001099800-26-000015Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r9 · c2 · span 916096–916103
11Section 03, Larry Wood OPTIONDEF 14A2026-03-260001099800-26-000015Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t96 · r3 · c1 · span 1838207–1838213
12Section 03, Daveen Chopra PSUDEF 14A2026-03-260001099800-26-000015Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r8 · c5 · span 915465–915472
13Section 03, Larry Wood PSUDEF 14A2026-03-260001099800-26-000015Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r9 · c5 · span 916476–916483
14Section 03, Bernard Zovighian PSUDEF 14A2026-03-260001099800-26-000015Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r4 · c5 · span 911389–911398
15Section 03, Bernard Zovighian OPTIONDEF 14A2026-03-260001099800-26-000015Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t95 · r2 · c1 · span 1830943–1830950
16Section 03, Scott Ullem PSUDEF 14A2026-03-260001099800-26-000015Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r5 · c2 · span 912096–912105
17Section 03, Scott Ullem PSUDEF 14A2026-03-260001099800-26-000015Section “Grants of Plan-Based Awards in Fiscal Year 2025” · grants of plan-based awards table. Filing ↗machine: t59 · r5 · c5 · span 912382–912391
18Section 07, pay ratioDEF 14A2026-03-260001099800-26-000015Section “CEO Pay Ratio”. As printed: 194 : 1. Filing ↗
19Section 08, Nicholas J. ValerianiDEF 14A2026-03-260001099800-26-000015Section “Director Compensation”. As printed: 494,956. Filing ↗machine: t42 · r9 · c4 · span 623292–623299
20Section 08, Leslie S. HeiszDEF 14A2026-03-260001099800-26-000015Section “Director Compensation”. As printed: 374,943. Filing ↗machine: t42 · r5 · c4 · span 618638–618645
21Section 08, Paul A. LaVioletteDEF 14A2026-03-260001099800-26-000015Section “Director Compensation”. As printed: 364,943. Filing ↗machine: t42 · r6 · c4 · span 619799–619806
22Section 08, Kieran T. GallahueDEF 14A2026-03-260001099800-26-000015Section “Director Compensation”. As printed: 349,970. Filing ↗machine: t42 · r4 · c4 · span 617477–617484
23Section 08, David T. FeinbergDEF 14A2026-03-260001099800-26-000015Section “Director Compensation”. As printed: 349,943. Filing ↗machine: t42 · r3 · c4 · span 616317–616324
24Section 08, Ramona SequeiraDEF 14A2026-03-260001099800-26-000015Section “Director Compensation”. As printed: 349,943. Filing ↗machine: t42 · r8 · c4 · span 622128–622135
25Section 08, Steven R. LorangerDEF 14A2026-03-260001099800-26-000015Section “Director Compensation”. As printed: 344,970. Filing ↗machine: t42 · r7 · c4 · span 620965–620972
26Section 08, Leslie C. DavisDEF 14A2026-03-260001099800-26-000015Section “Director Compensation”. As printed: 344,943. Filing ↗machine: t42 · r2 · c4 · span 615324–615338
27Section 08, Bernard ZovighianDEF 14A2026-03-260001099800-26-000015Section “Director Compensation”. As printed: 0. Filing ↗
28Section 02, Donald Bobo 2026-04-02Form 42026-04-020001225208-26-004249Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Donald Bobo 2026-04-02Form 42026-04-020001225208-26-004249Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Donald Bobo 2026-04-02Form 42026-04-020001225208-26-004249Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Donald Bobo 2026-04-02Form 42026-04-020001225208-26-004249Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Daniel J. Lippis 2026-04-06Form 42026-04-060001225208-26-004422Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Daniel J. Lippis 2026-04-06Form 42026-04-060001225208-26-004422Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Daniel J. Lippis 2026-04-06Form 42026-04-060001225208-26-004422Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Scott Ullem 2026-04-09Form 42026-04-090001225208-26-004476Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Scott Ullem 2026-04-09Form 42026-04-090001225208-26-004476Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Scott Ullem 2026-04-09Form 42026-04-090001225208-26-004476Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Scott Ullem 2026-04-09Form 42026-04-090001225208-26-004476Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Daniel J. Lippis 2026-05-01Form 42026-05-040001225208-26-004909Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Daniel J. Lippis 2026-05-01Form 42026-05-040001225208-26-004909Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Daniel J. Lippis 2026-05-01Form 42026-05-040001225208-26-004909Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Daniel J. Lippis 2026-05-01Form 42026-05-040001225208-26-004909Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Daniel J. Lippis 2026-05-01Form 42026-05-040001225208-26-004909Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Daniel J. Lippis 2026-05-01Form 42026-05-040001225208-26-004909Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Daniel J. Lippis 2026-05-01Form 42026-05-040001225208-26-004909Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Daniel J. Lippis 2026-05-01Form 42026-05-040001225208-26-004909Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Donald Bobo 2026-05-03Form 42026-05-040001225208-26-004907Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Daveen Chopra 2026-05-03Form 42026-05-040001225208-26-004908Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Scott Ullem 2026-05-03Form 42026-05-050001225208-26-004969Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Bernard Zovighian 2026-05-03Form 42026-05-050001225208-26-004968Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Bernard Zovighian 2026-05-03Form 42026-05-050001225208-26-004968Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Scott Ullem 2026-05-03Form 42026-05-050001225208-26-004969Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Scott Ullem 2026-05-03Form 42026-05-050001225208-26-004969Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Scott Ullem 2026-05-03Form 42026-05-050001225208-26-004969Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Bernard Zovighian 2026-05-03Form 42026-05-050001225208-26-004968Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Daveen Chopra 2026-05-07Form 42026-05-080001225208-26-005043Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Bernard Zovighian 2026-05-07Form 42026-05-110001225208-26-005131Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Wayne Markowitz 2026-05-07Form 42026-05-110001225208-26-005132Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Daniel J. Lippis 2026-05-07Form 42026-05-080001225208-26-005045Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Daveen Chopra 2026-05-07Form 42026-05-080001225208-26-005043Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Bernard Zovighian 2026-05-07Form 42026-05-110001225208-26-005131Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Donald Bobo 2026-05-07Form 42026-05-080001225208-26-005048Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Scott Ullem 2026-05-07Form 42026-05-080001225208-26-005047Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Donald Bobo 2026-05-07Form 42026-05-080001225208-26-005048Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Donald Bobo 2026-05-07Form 42026-05-080001225208-26-005048Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Annette Bruls 2026-05-07Form 42026-05-080001225208-26-005042Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Annette Bruls 2026-05-07Form 42026-05-080001225208-26-005042Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Annette Bruls 2026-05-07Form 42026-05-080001225208-26-005042Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Annette Bruls 2026-05-07Form 42026-05-080001225208-26-005042Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Daveen Chopra 2026-05-07Form 42026-05-080001225208-26-005043Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Daveen Chopra 2026-05-07Form 42026-05-080001225208-26-005043Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Andrew M. Dahl 2026-05-07Form 42026-05-080001225208-26-005044Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Andrew M. Dahl 2026-05-07Form 42026-05-080001225208-26-005044Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Daniel J. Lippis 2026-05-07Form 42026-05-080001225208-26-005045Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Wayne Markowitz 2026-05-07Form 42026-05-110001225208-26-005132Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Wayne Markowitz 2026-05-07Form 42026-05-110001225208-26-005132Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Bernard Zovighian 2026-05-07Form 42026-05-110001225208-26-005131Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Bernard Zovighian 2026-05-07Form 42026-05-110001225208-26-005131Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Bernard Zovighian 2026-05-07Form 42026-05-110001225208-26-005131Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Bernard Zovighian 2026-05-07Form 42026-05-110001225208-26-005131Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Donald Bobo 2026-05-07Form 42026-05-080001225208-26-005048Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Scott Ullem 2026-05-07Form 42026-05-080001225208-26-005047Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Daveen Chopra 2026-05-07Form 42026-05-080001225208-26-005043Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Daniel J. Lippis 2026-05-07Form 42026-05-080001225208-26-005045Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Wayne Markowitz 2026-05-07Form 42026-05-110001225208-26-005132Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Bernard Zovighian 2026-05-07Form 42026-05-110001225208-26-005131Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Wayne Markowitz 2026-05-07Form 42026-05-110001225208-26-005132Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Wayne Markowitz 2026-05-07Form 42026-05-110001225208-26-005132Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Daniel J. Lippis 2026-05-07Form 42026-05-080001225208-26-005045Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Daniel J. Lippis 2026-05-07Form 42026-05-080001225208-26-005045Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Andrew M. Dahl 2026-05-07Form 42026-05-080001225208-26-005044Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Andrew M. Dahl 2026-05-07Form 42026-05-080001225208-26-005044Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Donald Bobo 2026-05-07Form 42026-05-080001225208-26-005048Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Bernard Zovighian 2026-05-07Form 42026-05-110001225208-26-005131Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Bernard Zovighian 2026-05-07Form 42026-05-110001225208-26-005131Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Nicholas J. Valeriani 2026-05-08Form 42026-05-080001225208-26-005055Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Kieran T. Gallahue 2026-05-08Form 42026-05-080001225208-26-005050Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Kieran T. Gallahue 2026-05-08Form 42026-05-080001225208-26-005050Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Heisz Leslie Stone 2026-05-08Form 42026-05-080001225208-26-005051Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Ramona Sequeira 2026-05-08Form 42026-05-080001225208-26-005054Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Steven R. Loranger 2026-05-08Form 42026-05-080001225208-26-005053Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Paul A. LaViolette 2026-05-08Form 42026-05-080001225208-26-005052Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, David T. Feinberg 2026-05-08Form 42026-05-080001225208-26-005049Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Leslie C. Davis 2026-05-08Form 42026-05-080001225208-26-005046Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Steven R. Loranger 2026-05-08Form 42026-05-080001225208-26-005053Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Bernard Zovighian 2026-05-11Form 42026-05-120001225208-26-005172Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Scott Ullem 2026-05-11Form 42026-05-110001225208-26-005133Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Daniel J. Lippis 2026-05-11Form 42026-05-110001225208-26-005130Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Bernard Zovighian 2026-05-11Form 42026-05-120001225208-26-005172Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Scott Ullem 2026-05-11Form 42026-05-110001225208-26-005133Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Daveen Chopra 2026-05-11Form 42026-05-120001225208-26-005170Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Donald Bobo 2026-05-11Form 42026-05-120001225208-26-005171Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Donald Bobo 2026-05-11Form 42026-05-120001225208-26-005171Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Bernard Zovighian 2026-05-11Form 42026-05-120001225208-26-005172Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Bernard Zovighian 2026-05-11Form 42026-05-120001225208-26-005172Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Bernard Zovighian 2026-05-11Form 42026-05-120001225208-26-005172Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Bernard Zovighian 2026-05-11Form 42026-05-120001225208-26-005172Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Daveen Chopra 2026-05-11Form 42026-05-120001225208-26-005170Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Bernard Zovighian 2026-05-11Form 42026-05-120001225208-26-005172Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Donald Bobo 2026-05-11Form 42026-05-120001225208-26-005171Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Daveen Chopra 2026-05-11Form 42026-05-120001225208-26-005170Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Scott Ullem 2026-05-11Form 42026-05-110001225208-26-005133Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Donald Bobo 2026-05-15Form 42026-05-180001225208-26-005463Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Donald Bobo 2026-05-15Form 42026-05-180001225208-26-005463Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Daniel J. Lippis 2026-05-18Form 42026-05-180001225208-26-005464Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Daniel J. Lippis 2026-05-18Form 42026-05-180001225208-26-005464Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Daniel J. Lippis 2026-05-18Form 42026-05-180001225208-26-005464Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Daveen Chopra 2026-05-22Form 42026-05-220001225208-26-005576Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Donald Bobo 2026-05-27Form 42026-05-270001225208-26-005610Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Andrew M. Dahl 2026-05-29Form 42026-05-290001225208-26-005647Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Bernard Zovighian 2026-06-17Form 42026-06-170001225208-26-006103Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Daniel J. Lippis 2026-06-30Form 42026-06-300001225208-26-006263Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Daniel J. Lippis 2026-06-30Form 42026-06-300001225208-26-006263Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Daniel J. Lippis 2026-06-30Form 42026-06-300001225208-26-006263Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Daniel J. Lippis 2026-07-07Form 42026-07-070001225208-26-006535Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Theodora Mistras 2026-07-09Form 42026-07-100001225208-26-006578Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Theodora Mistras 2026-07-09Form 42026-07-100001225208-26-006578Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Theodora Mistras 2026-07-09Form 42026-07-100001225208-26-006578Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Theodora Mistras 2026-07-09Form 42026-07-100001225208-26-006578Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Daniel J. Lippis 2026-07-10Form 42026-07-100001225208-26-006576Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Daniel J. Lippis 2026-07-10Form 42026-07-100001225208-26-006576Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Daniel J. Lippis 2026-07-10Form 42026-07-100001225208-26-006576Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Annette Bruls 2026-07-11Form 42026-07-130001225208-26-006591Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Bernard Zovighian 2026-07-27Form 42026-07-270001225208-26-006743Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Bernard Zovighian 2026-07-27Form 42026-07-270001225208-26-006743Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Bernard Zovighian 2026-07-27Form 42026-07-270001225208-26-006743Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Wayne Markowitz 2026-07-28Form 42026-07-280001225208-26-006777Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Wayne Markowitz 2026-07-28Form 42026-07-280001225208-26-006777Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Wayne Markowitz 2026-07-28Form 42026-07-280001225208-26-006777Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Wayne Markowitz 2026-07-30Form 42026-07-300001225208-26-006853Insider equity transaction reported since the proxy statement. Filing ↗
151Section 06, 2026 voteForm 8-K2026-05-080001099800-26-000028Item 5.07 · say-on-pay result. As reported: 89.3% (votes for as printed: 424,961,639). Filing ↗
152Section 06, 2025 voteForm 8-K2025-05-080001099800-25-000026Item 5.07 · say-on-pay result. As reported: 88.01% (votes for as printed: 412,893,480.47). Filing ↗
153Section 06, 2024 voteForm 8-K2024-05-080001099800-24-000045Item 5.07 · say-on-pay result. As reported: 91.1% (votes for as printed: 433,346,235.39). Filing ↗
154Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
155Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
156Section 09b board cost (computed)ComputedcomputedCash 745,054 + equity 2,229,557 + all other 0 = 2,974,611, summed across the director compensation table rows.machine: formula: Σ = 2,974,611
157Baxter International Inc., Section 10b CEO totalDEF 14A2026-03-230001628280-26-020330CEO total compensation as printed in Baxter International Inc.'s own proxy. As printed: 29,805,182. Filing ↗machine: r4 · c30 · span 1451066–1451076
158Abbott Laboratories, Section 10b CEO totalDEF 14A2026-03-130001308179-26-000064CEO total compensation as printed in Abbott Laboratories's own proxy. As printed: 24,198,660. Filing ↗machine: span 1245488–1245498
159Boston Scientific Corporation, Section 10b CEO totalDEF 14A2026-03-180000885725-26-000025CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. Filing ↗machine: r2 · c27 · span 1249807–1249817
160Medtronic plc, Section 10b CEO totalDEF 14A2026-08-170001613103-26-000010CEO total compensation as printed in Medtronic plc's own proxy. As printed: 22,940,252. Filing ↗machine: span 988220–988230
161Stryker Corporation, Section 10b CEO totalDEF 14A2026-03-230000310764-26-000013CEO total compensation as printed in Stryker Corporation's own proxy. As printed: 21,401,495. Filing ↗machine: t101 · r2 · c7 · span 1584979–1584989
162Intuitive Surgical, Inc., Section 10b CEO totalDEF 14A2026-03-130001035267-26-000023CEO total compensation as printed in Intuitive Surgical, Inc.'s own proxy. As printed: 20,997,480. Filing ↗machine: r2 · c48 · span 762289–762299
163Align Technology, Inc., Section 10b CEO totalDEF 14A2026-04-070001097149-26-000023CEO total compensation as printed in Align Technology, Inc.'s own proxy. As printed: 19,193,988. Filing ↗machine: r2 · c42 · span 933168–933178
164GE Healthcare Technologies Inc., Section 10b CEO totalDEF 14A2026-03-190001932393-26-000021CEO total compensation as printed in GE Healthcare Technologies Inc.'s own proxy. As printed: 18,562,794. Filing ↗machine: t113 · r3 · c20 · span 924977–924987
165Edwards Lifesciences Corp (subject), Section 10b CEO totalDEF 14A2026-03-260001099800-26-000015CEO total compensation as printed in Edwards Lifesciences Corp's own proxy. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451
166Becton, Dickinson and Company, Section 10b CEO totalDEF 14A2025-12-180001628280-25-057846CEO total compensation as printed in Becton, Dickinson and Company's own proxy. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295
167Zimmer Biomet Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-010001193125-26-135661CEO total compensation as printed in Zimmer Biomet Holdings, Inc.'s own proxy. As printed: 16,106,550. Filing ↗machine: t111 · r3 · c16 · span 1895785–1895795
168The Cooper Companies, Inc., Section 10b CEO totalDEF 14A2026-02-240001628280-26-011110CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. Filing ↗machine: t120 · r3 · c14 · span 744904–744914
169Hologic, Inc., Section 10b CEO totalDEF 14A2025-01-160001140361-25-001287CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674
170ResMed Inc., Section 10b CEO totalDEF 14A2025-10-020000943819-25-000079CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 14,674,543. Filing ↗machine: span 1328668–1328678
171IDEXX Laboratories, Inc., Section 10b CEO totalDEF 14A2026-03-270000874716-26-000064CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018
172Agilent Technologies, Inc., Section 10b CEO totalDEF 14A2026-02-060001193125-26-040286CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992
173Illumina, Inc., Section 10b CEO totalDEF 14A2026-04-090001193125-26-149669CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536
174DexCom, Inc., Section 10b CEO totalDEF 14A2026-04-150001093557-26-000061CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. Filing ↗machine: span 940364–940373
175Section 10a, Align Technology, Inc. reciprocityDEF 14A0001097149-26-000023Align Technology, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
176Section 10a, Agilent Technologies, Inc. reciprocityDEF 14A0001193125-26-040286Agilent Technologies, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
177Section 10a, DexCom, Inc. reciprocityDEF 14A0001093557-26-000061DexCom, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
178Section 10a, Hologic, Inc. reciprocityDEF 14A0001140361-25-001287Hologic, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
179Section 10a, Zimmer Biomet Holdings, Inc. reciprocityDEF 14A0001193125-26-135661Zimmer Biomet Holdings, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
180Section 10a, ResMed Inc. reciprocityDEF 14A0000943819-25-000079ResMed Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
181Section 10a, The Cooper Companies, Inc. reciprocityDEF 14A0001628280-26-011110The Cooper Companies, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
182Section 10a, Intuitive Surgical, Inc. reciprocityDEF 14A0001035267-26-000023Intuitive Surgical, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
183Section 10a, Becton, Dickinson and Company reciprocityDEF 14A0001628280-25-057846Becton, Dickinson and Company's most recent proxy was read; its disclosed peer group does not include Edwards Lifesciences Corp. Filing ↗
184Section 10a, Baxter International Inc. reciprocityDEF 14A0001628280-26-020330Baxter International Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
185Section 10a, GE Healthcare Technologies Inc. reciprocityDEF 14A0001932393-26-000021GE Healthcare Technologies Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
186Section 10a, IDEXX Laboratories, Inc. reciprocityDEF 14A0000874716-26-000064IDEXX Laboratories, Inc. names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
187Section 10a, Boston Scientific Corporation reciprocityDEF 14A0000885725-26-000025Boston Scientific Corporation names Edwards Lifesciences Corp in its own disclosed peer group (read from its most recent proxy). Filing ↗
188Section 10a, Stryker Corporation reciprocityDEF 14A0000310764-26-000013Stryker Corporation's most recent proxy was read; its disclosed peer group does not include Edwards Lifesciences Corp. Filing ↗